Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bluefish Pharmaceuticals, a developer, manufacturer of generic pharmaceuticals, has purchased all the assests of BioPhausia subsidiary BMM Pharma.
Subscribe to our email newsletter
The purchase price includes a sum of $4m for shares in BMM Pharma and approximately $2m for the inventory.
The acquisition allows Bluefish to increase the value of its existing product portfolio by adding generic pharmaceuticals within the niche segment.
Bluefish has 68 products in its portfolio of which 19 pharmaceutical products are of BMM Pharma which are used in pain, inflammation and gastrointestinal therapy.
Bluefish CEO and founder Karl Karlsson said their scale, together with their broad presence throughout the rest of Europe, offers new pan-European business opportunities.